Blogs
Healthcare and Medtech Research Reports
Aug 16, 2019
The recent acquisition of Relief Therapeutics by Sonnet BioTherapeutics will surely fuel the growth of Chemotherapy-Induced Peripheral Neuropathy (CIPN) therapy market. Sonnet plans to commence the development of its promising candidate SON-080 for CIPN treatment. Peripheral Neuropathy is a set of complications cau...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Newsletter/Whitepaper